Locations:
SearchAdvertisement
Offers a new option for patients 60 and older with relapsed/refractory disease
Blinatumomab plus chemotherapy improves overall survival and relapse-free survival over chemotherapy alone
Study assesses the impact of donor source and post-transplant prophylaxis for patients receiving a hematopoietic cell transplant
Novel regimen may help overcome the shortcomings of traditional chemotherapy in geriatric population
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Key findings from national database study
Drug beats standard care for the treatment of relapsed or refractory ALL
A deep dive into survival differences between pediatric and adolescent/young adult leukemia patients
Findings of a new study emphasize the importance of psychosocial support for patients and families
Study results from ASH 2019 shed light on treatment
Two-year follow-up confirms initial findings of the INO-VATE trial
Advertisement
Advertisement